Bayer Logo Bayer Logo Bayer Logo Bayer Logo

Efficacy & Safety
PK Across Age

The confidence of a consistent PK profile across age groups1

Kovaltry is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) for adults, adolescents and children of all ages.

Kovaltry logo

Comparable population PK results in children across age groups1*

half life
half life

Robust population PK results for adolescents and adults1*

half life
half life

*The population PK model was developed based on all available FVIII measurements throughout the LEOPOLD clinical studies.

†Data are geometric means.

‡Area under the curve calculated for a dose of 50 IU/kg.

LEOPOLD, Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease; PK, pharmacokinetics; PTP, previously treated patient


  • Kovaltry [Summary of Product Characteristics]. Leverkusen, Germany: Bayer; 2017. Return to content